Valneva SE Sponsored ADR (NASDAQ:VALN) Sees Large Increase in Short Interest

Valneva SE Sponsored ADR (NASDAQ:VALN) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 161,000 shares, a growth of 1,198.4% from the September 30th total of 12,400 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is currently 1.8 days. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is currently 1.8 days. Approximately 0.2% of the company’s shares are sold short.

Valneva Stock Down 3.0%

Shares of Valneva stock opened at $9.26 on Tuesday. The company has a quick ratio of 1.77, a current ratio of 2.27 and a debt-to-equity ratio of 0.66. Valneva has a 12 month low of $3.62 and a 12 month high of $12.25. The business has a fifty day simple moving average of $9.97 and a 200 day simple moving average of $7.88. The stock has a market cap of $796.17 million, a PE ratio of -9.45 and a beta of 1.86.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The business had revenue of $54.84 million during the quarter, compared to analysts’ expectations of $46.28 million. Research analysts predict that Valneva will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Valneva stock. Frazier Life Sciences Management L.P. bought a new position in shares of Valneva SE Sponsored ADR (NASDAQ:VALN) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,458,333 shares of the company’s stock, valued at approximately $8,240,000. Frazier Life Sciences Management L.P. owned approximately 1.71% of Valneva at the end of the most recent quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on VALN. Weiss Ratings reissued a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Jefferies Financial Group set a $14.00 target price on Valneva and gave the company a “buy” rating in a research note on Monday, August 25th. Wall Street Zen raised Valneva to a “hold” rating in a research note on Saturday, September 6th. Guggenheim lowered their target price on Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, September 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Valneva has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.